Exelixis Employs Novel Adaptive Trial Design To Evaluate Cabozantinib In Multiple Cancers
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Exelixis Inc.'s investigational cancer drug cabozantinib demonstrated activity in patients with nine kinds of cancer as part of a single Phase II trial that employs a novel adaptive randomized discontinuation design. The company presented updated data from the trial in three sessions at the American Society of Clinical Oncology meeting June 3-7 in Chicago.
You may also be interested in...
Can Wealth Of Molecular Data Enable Promise Of Chemoprevention?
The same advances in scientific understanding of the molecular basis of cancer that have propelled the rise of targeted oncologics also hold out the tantalizing prospect of expanded chemoprevention in cancer, the American Association for Cancer Research suggests in its Cancer Progress Report 2011.
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.